Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

@article{NavarroMilln2012SystematicRO,
  title={Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.},
  author={Iris Navarro-Mill{\'a}n and Jasvinder A Singh and Jeffrey R. Curtis},
  journal={Clinical therapeutics},
  year={2012},
  volume={34 4},
  pages={788-802.e3}
}
BACKGROUND Tocilizumab (TCZ), a humanized anti-interleukin-6 receptor monoclonal antibody, represents a new treatment strategy for patients with rheumatoid arthritis (RA) and is currently approved in the United States for RA patients who have failed to improve with at least one anti-tumor necrosis factor therapy. OBJECTIVE The goal of this study was to summarize the efficacy and safety profile of TCZ. METHODS A systematic literature review was conducted to identify English-language articles… CONTINUE READING